Anti-MAG antibody detection reagent, preparation method and application thereof, kit using detection reagent and detection method
Through glycosylation modification of MAG protein and recombinant plasmid expression technology, the detection sensitivity of anti-MAG antibodies is improved, the problems of high diagnostic cost and low accuracy in the prior art are solved, and rapid and accurate detection of anti-MAG antibodies are achieved. Reduces the difficulty and cost of clinical diagnosis.
Patent Information
- Application Number
- CN202411178518.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-19
AI Technical Summary
The existing anti-MAG antibody detection methods have problems with low accuracy and sensitivity, which leads to high diagnostic cost, long time and difficulty in accurately diagnosed multiple neuropathy.
By glycosylation modification of MAG proteins, a glycoprotein complex is formed, and the structure of the protein is changed, thereby improving the binding rate and detection sensitivity of anti-MAG antibodies and antigens. Recombinant plasmids are used to express glycosylated MAG genes under low temperature conditions, and prepared Anti-MAG antibody detection reagents and combined with CBA detection methods for rapid and accurate detection.
It improves the detection rate and detection sensitivity of anti-MAG antibodies, reduces the difficulty and detection cost of clinical diagnosis of diseases, and provides a fast and accurate detection method to assist clinical diagnosis.
Smart Images

Figure FT_1 
Figure FT_2
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of antibody detection, and in particular to an anti-MAG antibody detection reagent and a preparation method and application thereof, a kit using the detection reagent, and a detection method. Background Art
[0002] Myelin-associated glycoprotein (MAG) is a glycoprotein present on the myelin sheath, with a molecular weight of about 130 kDa. Its basic structure consists of multiple regions, including: an N-terminal region containing a signal peptide sequence and a glycosylation site; an Ig-like region containing five repeating units, each of which has two cysteine residues connected to form a folded structure; a glycosylation region containing a large number of glycosylation sites; a transmembrane region containing a transmembrane α-helix and an extracellular C-terminal; and a C-terminal region containing one glycosylation site and a short peptide sequence, which is involved in the adhesion and signal transduction of the protein itself. The special feature of the MAG structure lies in the repeating units of its Ig-like region, which are connected to each other through disulfide bonds of cysteine residues to form a long and tight protein chain. In addition, MAG has a variety of glycosylation modifications, which can affect its adhesion and structural stability, and interact with other adhesion proteins on neuronal axons to jointly maintain the structure and function of the myelin sheath.
[0003] The main function of MAG is to form adhesion between neuronal axons and myelin sheaths, and participate in maintaining the structure and stability of myelin sheaths. Its mechanism is the interaction between complementary receptors on the surface of adjacent axons. Therefore, in myelin-related diseases including sensory neuropathy, motor neuropathy, multiple sclerosis, and diabetic neuropathy, anti-MAG antibodies attack the nervous system tissue itself, triggering axonal degeneration of demyelination, which is the main cause of the occurrence and progression of these diseases. Among them, the most prominent is anti-MAG antibody-related peripheral neuropathy, which is a rare immune-mediated disease of the nervous system. Patients will produce anti-MAG antibodies, which will lead to abnormal destruction of neuronal axons and myelin sheath structures, causing peripheral neuropathy. The main clinical manifestations include motor and sensory disorders, autonomic dysfunction, and some special symptoms such as muscle atrophy and purple fingers.
[0004] At present, the main diagnostic methods for this type of polyneuropathy are: 1. Medical history and physical examination to look for pathological signs; 2. Neurological examination, by testing the patient's sensory, muscle strength, reflex and coordination functions to confirm whether the nervous system is damaged; 3. Imaging examination, through magnetic resonance imaging and electronic computer tomography, to observe changes in nervous system tissue, including brain, spinal cord and peripheral nerves; 4. Neuroelectromyography, neuroelectromyography is a diagnostic method that can evaluate nerve and muscle function, and can detect abnormalities in nerve conduction velocity, muscle electrical activity and muscle contraction; 5. Cerebrospinal fluid examination, cerebrospinal fluid examination can detect immunological markers of polyneuropathy. For example, when the symptoms of multiple sclerosis worsen, the IgG level and the number of oligoclonal bands in the cerebrospinal fluid will increase.
[0005] Although this type of polyneuropathy can be classified according to the cause, the type of nerves affected, or the development of the disease. Currently, the diagnosis of peripheral neuropathy and polyneuritis is clinical symptom evaluation, neuroelectrophysiological testing, neuroimaging, and neurobiological tissue examination. These diagnostic methods are costly, time-consuming, and easily affected by diseases with similar symptoms, thus failing to accurately diagnose the type of disease. The occurrence and progression of these diseases are undoubtedly closely related to the patient's own anti-MAG antibodies.
[0006] Therefore, based on the importance of anti-MAG antibody detection, there is an urgent need to provide a detection method and detection kit for anti-MAG antibodies with higher accuracy and sensitivity. Summary of the invention
[0007] In order to improve the accuracy and sensitivity of anti-MAG antibody detection, the present application provides an anti-MAG antibody detection reagent and a preparation method and application thereof, a kit using the detection reagent, and a detection method.
[0008] During the research and development process, it was found that the detection rate of MAG antigen protein directly expressed using the full-length sequence was low, and positive samples were often detected as negative, or the antibody titer test results were inaccurate. This is because the post-translational modification process of the MAG antigen protein is incomplete and the degree of glycosylation is low, resulting in poor antibody binding. In order to solve this problem, the present application performs glycosylation modification on the MAG protein. The sugar group will bind to the protein skeleton to form a glycoprotein complex, change the structure of the protein, thereby promoting the binding of anti-MAG antibodies to the antigen, and improving the detection rate and sensitivity.
[0009] Currently, in clinical diagnosis, the diagnosis of MAG antibody-related diseases is time-consuming, costly, and difficult to confirm. In order to reduce the cost of testing and assist clinical diagnosis, the present application provides a test kit that can quickly and accurately detect anti-MAG antibodies in patient serum or cerebrospinal fluid samples, reducing the difficulty of clinical diagnosis of the disease.
[0010] In a first aspect, the present application provides a method for preparing an anti-MAG antibody detection reagent, using the following technical solution: A method for preparing an anti-MAG antibody detection reagent, the preparation method specifically comprising the following steps: (1) Construction of recombinant plasmid; The recombinant plasmids include a recombinant plasmid with a nucleotide sequence encoding a MAG protein and a recombinant plasmid with a nucleotide sequence encoding a glycosyltransferase B3GAT1; The nucleotide sequence encoding the MAG protein includes the nucleotide sequence shown in SEQ ID NO: 1; The nucleotide sequence encoding glycosyltransferase B3GAT1 includes the nucleotide sequence shown in SEQ ID NO: 2; (2) co-transfecting the recombinant plasmid into mammalian cells and culturing them at low temperature to obtain cell plates expressing the glycosylated MAG gene; the mammalian cells are HEK 293T cells; The temperature used for the low temperature culture is 25-35°C, and the culture time is 48-72h; (3) Fixing the cell slide expressing the glycosylated MAG gene with a fixing solution to obtain an anti-MAG antibody detection reagent.
[0011] In the present application, the culture after transfection is carried out under low temperature conditions. The cells grow slowly under low temperature conditions, which is convenient for controlling the cell density and is conducive to the overexpression of glycosylated MAG.
[0012] To maintain vigorous growth of cultured cells, a constant and appropriate temperature is required. The standard temperature for HEK293T cell culture used in this application is 36.5±0.5°C. When the cells are placed at 25-35°C, the cells can still survive and grow, but the proliferation rate is slower than that of cells cultured at 37°C, which is beneficial to prolong the cell culture time and increase the expression of glycosylated MAG.
[0013] Cultivating at low temperature for 48-72 hours can effectively control the cell density after transfection, at which time a large amount of MAG protein will be expressed on the cell membrane. After fixation and staining, obvious positive cell membrane staining results will be observed under a fluorescence microscope.
[0014] Optionally, the preparation process temperature of the anti-MAG antibody detection reagent is no higher than 35°C.
[0015] In a second aspect, the present application provides an anti-MAG antibody detection reagent, which is prepared using the above preparation method.
[0016] Optionally, when the sample is tested using the detection reagent, the temperature of the detection process is no higher than 35°C.
[0017] Optionally, the detection process is carried out at room temperature.
[0018] In a third aspect, the present application provides a use of the above-mentioned anti-MAG antibody detection reagent in the preparation of a product for detecting anti-MAG antibodies.
[0019] In a fourth aspect, the present application provides a CBA detection kit, which includes the above-mentioned anti-MAG antibody detection reagent.
[0020] In a fifth aspect, the present application provides a CBA detection method using the above-mentioned anti-MAG antibody detection reagent, using the following technical solution: A CBA detection method using the above anti-MAG antibody detection reagent, the detection method specifically comprises the following steps: Add the sample to the reaction well of the anti-MAG antibody detection reagent and react in the dark; then wash with buffer and soak in a dye jar. After the reaction, take out and discard the liquid in the reaction well; continue to add fluorescent secondary antibody and continue to react in the dark; then wash with buffer, add sealing medium, and observe the results.
[0021] In summary, the present application includes at least one of the following beneficial technical effects: In the present application, MAG is subjected to glycosylation modification, and the sugar group will bind to the protein backbone to form a glycoprotein complex, thereby changing the structure of the protein, thereby promoting the binding of anti-MAG antibodies to antigens and improving the detection rate and sensitivity of anti-MAG antibodies.
[0022] The present application provides a test kit, which can quickly and accurately detect anti-MAG antibodies in patient serum or cerebrospinal fluid samples, reduce the difficulty of clinical diagnosis of the disease, and thus effectively reduce the cost of testing. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 It is a roadmap of the preparation method of the embodiments and comparative examples in this application.
[0024] Figure 2 These are the test results of three positive serum samples using the test reagents prepared in the examples and comparative examples of this application. DETAILED DESCRIPTION
[0025] Before describing the embodiments of the present application in detail, it should be understood that the terms used herein are only used for the purpose of describing specific embodiments. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by ordinary technicians in the field to which the terms belong.
[0026] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of this application, unless otherwise specified, the meaning of "plurality" is two or more.
[0027] The endpoints and any values of the ranges disclosed in this application are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0028] In the present application, the terms "comprise" or "include" are open expressions, that is, including the contents specified in the present application but not excluding other contents.
[0029] The present application provides a method for preparing an anti-MAG antibody detection reagent, an anti-MAG antibody detection reagent prepared by the preparation method, and use of the anti-MAG antibody detection reagent in preparing a product for detecting anti-MAG antibodies.
[0030] The above preparation method specifically comprises the following steps: (1) Construction of recombinant plasmid; The recombinant plasmids include a recombinant plasmid with a nucleotide sequence encoding a MAG protein and a recombinant plasmid with a nucleotide sequence encoding a glycosyltransferase B3GAT1; The nucleotide sequence encoding the MAG protein includes the nucleotide sequence shown in SEQ ID NO: 1; The nucleotide sequence encoding glycosyltransferase B3GAT1 includes the nucleotide sequence shown in SEQ ID NO: 2; (2) co-transfecting the recombinant plasmid into mammalian cells and culturing them at low temperature to obtain cell plates expressing the glycosylated MAG gene; the mammalian cells are HEK 293T cells; The temperature used for the low temperature culture is 25-35°C, and the culture time is 48-72h; (3) Fixing the cell slide expressing the glycosylated MAG gene with a fixing solution to obtain an anti-MAG antibody detection reagent.
[0031] The present application also provides a CBA detection kit comprising the above-mentioned anti-MAG antibody detection reagent, and a CBA detection method using the above-mentioned anti-MAG antibody detection reagent.
[0032] The above CBA detection method specifically comprises the following steps: Add the sample to the reaction well of the anti-MAG antibody detection reagent and react in the dark; then wash with buffer and soak in a dye jar. After the reaction, take out and discard the liquid in the reaction well; continue to add fluorescent secondary antibody and continue to react in the dark; then wash with buffer, add sealing medium, and observe the results.
[0033] In order to make the purpose, technical scheme and advantages of the present application clearer, the technical scheme in the embodiments of the present application will be clearly and completely described below in conjunction with the accompanying drawings. Based on the embodiments of the present application, all other embodiments obtained by those skilled in the art without making creative work belong to the scope of protection of the present application. The embodiments described below are exemplary and are only used to explain the present application, and cannot be understood as limiting the present application.
[0034] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0035] The present application is further described in detail below with reference to the embodiments.
[0036] Preparation Example Preparation Example 1 This preparation example provides a nucleotide sequence encoding a MAG protein. The nucleotide sequence includes the nucleotide sequence shown in SEQ ID NO: 1. The specific steps are as follows: (1) Select a human tissue or cell, extract genomic RNA, and prepare cDNA by reverse transcription.
[0037] (2) Design corresponding homologous recombination upstream and downstream primers for the MAG gene, and use the primers to perform PCR amplification on the MAG gene fragment to obtain the full-length CDS region (NCBI Reference Sequence: NM_002361), corresponding to the sequence SEQ ID NO: 1.
[0038] Preparation Example 2 This preparation example provides a nucleotide sequence encoding glycosyltransferase B3GAT1. The nucleotide sequence includes the nucleotide sequence shown in SEQ ID NO: 2. The specific steps are as follows: (1) Select a human tissue or cell, extract genomic RNA, and prepare cDNA by reverse transcription.
[0039] (2) Design corresponding homologous recombination upstream and downstream primers for the glycosyltransferase B3GAT1 gene, and use the primers to perform PCR amplification on the B3GAT1 gene fragment to obtain the full-length CDS region (NCBI Reference Sequence: NM_054025), corresponding to the sequence SEQ ID NO: 2.
[0040] Example This embodiment provides an anti-MAG antibody detection reagent.
[0041] The preparation method of the above anti-MAG antibody detection reagent is as follows Figure 1 The pathway shown in the Glycosylated MAG in FIG. 1 includes the following steps: 1. Construction of recombinant plasmid (1) Prepare recombinant plasmid. The specific steps are as follows: The nucleotide sequence encoding the MAG protein provided in Preparation Example 1, the nucleotide sequence encoding the glycosyltransferase B3GAT1 provided in Preparation Example 2, and the vector fragment were recovered and purified respectively, and connected using homologous recombination technology, and the target DNA fragment was inserted into the plasmid vector (pcDNA3.1) to obtain recombinant plasmids pcDNA3.1-MAG and pcDNA3.1-B3GAT1, respectively.
[0042] (2) Introduce the recombinant plasmids into DH5α competent cells, clone the plasmids and extract the plasmids. The specific steps are as follows: a. Introduce the above recombinant plasmid into DH5α competent cells.
[0043] b. Spread the DH5α competent cells introduced with the recombinant plasmid on an LB plate containing Amp.
[0044] c. Place the coated LB plate in a 37°C incubator for culture.
[0045] d. Large-scale extraction of plasmids from DH5α competent cells.
[0046] e. Perform restriction enzyme digestion on the plasmid and send it for sequencing.
[0047] The sequencing results showed that the recombinant plasmid was successfully constructed.
[0048] 2. Preparation of cell slides expressing glycosylated MAG (1) Culture of HEK 293T cells a. Take out the HEK 293T cells from liquid nitrogen, quickly put them into a 37°C water bath, and gently shake the cryovial to thaw the cryopreservation solution.
[0049] b. Transfer the thawed cells to a centrifuge tube containing culture medium, collect the cells by centrifugation, centrifuge at 1500 rpm for 3 minutes at room temperature, and discard the supernatant.
[0050] c. Suspend the cells with complete culture medium, inoculate into the culture flask, shake well, and culture at 37°C and 10% CO2 saturated humidity until the cells are fully grown.
[0051] d. Discard the old culture medium, rinse the cells with PBS buffer, digest the cells with 0.25% trypsin, and add an equal volume of complete culture medium to terminate the digestion.
[0052] e. Transfer the digested cells to a 15 mL centrifuge tube and collect the cells by centrifugation at 1500 rpm for 3 min.
[0053] f. Add complete culture medium, blow the cells to make a single cell suspension, subculture at a ratio of 1:5, and expand the culture at 37°C and 10% CO2 saturated humidity.
[0054] (2) Cell plating and transfection a. After three subcultures, wait until the cells grow to a good state and have an appropriate density.
[0055] b. Discard the old culture medium, rinse the cells with PBS, digest the cells with 0.25% trypsin, add an equal volume of complete culture medium to terminate the digestion, transfer to a 15 mL centrifuge tube, centrifuge at 1500 rpm for 3 min to collect the cells, and discard the supernatant.
[0056] c. Add 1 mL of complete culture medium to resuspend the cells. Pipette 150-200 μL of cell suspension according to the cell density and add it to a 6-well plate pretreated with the adhesion reagent and containing 2 mL of complete culture medium, and mix evenly.
[0057] d. When the cell density reached 80-90%, the recombinant plasmids pcDNA3.1-MAG and pcDNA3.1-B3GAT1 were co-transfected into HEK293T cells by cationic liposome transfection.
[0058] e. After transfection, the cells were cultured at 32°C and 10% CO2 under saturated humidity conditions.
[0059] f. Discard the culture medium at 6-h intervals, add 1 mL of serum-free culture medium for rinsing and then remove, add 2 mL of complete culture medium and continue culturing for 48 h to obtain cell slides that express a large amount of glycosylated MAG on the cell membrane.
[0060] 3. Preparation of anti-MAG antibody detection reagent The culture medium was removed, and 1 mL of PBS buffer was added to rinse the obtained cell slides three times. The washed cell slides were placed in the prepared fixative (cold acetone) and fixed for 10 min.
[0061] After fixation, the fixative was removed, and 1 mL of PBS buffer was added for rinsing 3 times. The fixative was washed off to obtain the CBA antigen piece, which was the anti-MAG antibody detection reagent.
[0062] Add desiccant and place in a drying room for air drying. All subsequent steps should be completed in a drying room with constant temperature and humidity. Cut and dry the anti-MAG antibody detection reagent, paste it on a 4-well mosaic plate, and store it for a long time at 4-8°C.
[0063] Comparative Example This comparative example provides an anti-MAG antibody detection reagent. The preparation method of the anti-MAG antibody detection reagent is as follows: Figure 1 The pathway shown in Non-glycosylated MAG.
[0064] The difference between the preparation method of the above anti-MAG antibody detection reagent and Example 1 is that in the preparation method of the detection reagent of this comparative example, the target gene used only includes the CDS region sequence of the MAG gene, which is the nucleotide sequence shown in SEQ ID NO:1.
[0065] Detection test The samples were tested using the detection reagents of the embodiment and the comparative example. The samples can be 10-fold diluted serum samples or undiluted cerebrospinal fluid samples. Here are three positive serum samples.
[0066] The detection method using the above detection reagent is as follows: (1) Soak the prepared anti-MAG antibody detection reagent in PBS buffer for 5 minutes. After the reaction, remove and discard the liquid in the reaction well.
[0067] (2) Add 10-fold diluted serum samples to the reaction wells of the anti-MAG antibody detection reagent in sequence, 50 μL per well, and place in a wet box for reaction for 30 minutes.
[0068] (3) After the reaction is completed, use PBS buffer to gently rinse the sample in the reaction well from one side and soak it in the dye tank for 5 minutes. After the reaction is completed, remove and discard the liquid in the reaction well.
[0069] (4) Add 50 μL of fluorescent secondary antibody (goat anti-human secondary antibody labeled with fluorescent Dylight 488) to the reaction well, and ensure that the fluorescent secondary antibody is in good contact with the reaction well. Place in a wet box for reaction for 30 minutes, and avoid light throughout the reaction process.
[0070] (5) Repeat step (3) and add mounting medium (a mixture of glycerol and PBS buffer in a ratio of 1:9 (v:v)) to the reaction wells and carefully cover with a coverslip to avoid bubbles.
[0071] (6) Observe the results under a fluorescence microscope.
[0072] The test results of the embodiments and comparative examples are as follows Figure 2 shown.
[0073] Depend on Figure 2 It can be seen that the comparative example uses an unglycosylated MAG gene CDS region sequence, and the background signal of the test result is high, which interferes with the interpretation of the antibody titer, and the expression rate is low; while the glycosylated MAG gene CDS region sequence is used in the embodiment, the cell staining morphology is greatly improved, the cell membrane staining is clearer, the expression efficiency is greatly improved, the sensitivity is enhanced, and especially the influence of the background value is greatly reduced. The interpretation of the antibody titer is more accurate, which is conducive to the clinical analysis of anti-MAG antibody-related diseases through the CBA detection method. By comparison, it can be seen that the present application can effectively improve the detection rate and sensitivity of anti-MAG antibodies by glycosylation of MAG and the anti-MAG antibody detection material prepared by using it.
[0074] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0075] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present application.
Claims
1. A method for preparing an anti-MAG antibody detection reagent, characterized in that: The preparation method specifically comprises the following steps: (1) Construction of recombinant plasmid; The recombinant plasmids include a recombinant plasmid with a nucleotide sequence encoding a MAG protein and a recombinant plasmid with a nucleotide sequence encoding a glycosyltransferase B3GAT1; The nucleotide sequence encoding the MAG protein includes the nucleotide sequence shown in SEQ ID NO: 1; The nucleotide sequence encoding glycosyltransferase B3GAT1 includes the nucleotide sequence shown in SEQ ID NO: 2; (2) co-transfecting the recombinant plasmid into mammalian cells and culturing them at low temperature to obtain cell plates expressing the glycosylated MAG gene; the mammalian cells are HEK 293T cells; The temperature used for the low temperature culture is 25-35°C, and the culture time is 48-72h; (3) Fixing the cell slide expressing the glycosylated MAG gene with a fixing solution to obtain an anti-MAG antibody detection reagent.
2. The preparation method according to claim 1, characterized in that: The temperature during the preparation of the anti-MAG antibody detection reagent is no higher than 35°C.
3. An anti-MAG antibody detection reagent, characterized in that: The anti-MAG antibody detection reagent is prepared by the preparation method described in any one of claims 1-2.
4. The anti-MAG antibody detection reagent according to claim 3, characterized in that: When the sample is tested using the test reagent, the temperature during the test is no higher than 35°C.
5. The anti-MAG antibody detection reagent according to claim 4, characterized in that: The testing process was carried out at room temperature.
6. Use of the anti-MAG antibody detection reagent according to claim 3 in preparing a product for detecting anti-MAG antibodies.
7. A CBA detection kit, characterized in that: The CBA detection kit comprises the anti-MAG antibody detection reagent according to claim 3.
8. A CBA detection method using the anti-MAG antibody detection reagent of claim 3, characterized in that: The detection method specifically includes the following steps: adding a sample to the reaction well of the anti-MAG antibody detection reagent for light-proof reaction; then washing with a buffer solution, soaking in a dye vat, taking out and discarding the liquid in the reaction well after completion; continuing to add a fluorescent secondary antibody to continue the light-proof reaction; then washing with a buffer solution, adding a sealing medium, and observing the results.
Citation Information
Cited By
Recombinant protein for detecting anti-myelin sheath related glycoprotein MAG antibody and detection reagent thereof
CN120137059A
